Summary & Overview
HCPCS J1814: Insulin (lyumjev), per 5 units
HCPCS Level II code J1814 designates billing for insulin (lyumjev) measured per 5 units and is used when supplying or administering this rapid-acting insulin formulation. Nationally, accurate coding for insulin products matters for clinical continuity, pharmacy and medical benefit alignment, and consistent claims processing for diabetes management. Common sites of service include outpatient clinics, physician offices, infusion centers, and ambulatory care settings where insulin is administered or dispensed.
Key payers covered in this summary include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the code’s clinical context, expected service lines and sites of care, and typical payer coverage considerations. The publication outlines benchmarks and coding guidance relevant to billing workflow, summarizes common modifiers and administrative flags for related services (Data not available in the input), and highlights policy updates that influence medical benefit versus pharmacy benefit routing for insulin products (Data not available in the input).
This report is intended for revenue cycle staff, billing professionals, and policy analysts seeking a concise reference to HCPCS Level II code J1814, its clinical role in diabetes care, and the payer landscape that influences reimbursement and claims adjudication.
Billing Code Overview
HCPCS Level II code J1814 describes insulin (lyumjev), per 5 units. This code represents billing for a rapid-acting insulin formulation measured and reimbursed in 5-unit increments. The service type is medication administration/supply for glycemic management in patients with diabetes. The typical site of service for services billed with this code includes outpatient clinics, physician offices, infusion centers, and other ambulatory care settings where insulin is supplied or administered to patients.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with type 1 or type 2 diabetes requiring rapid-acting insulin for prandial glucose control or correction dosing. The patient presents to an outpatient endocrinology clinic, diabetes education center, or a primary care office for medication management; alternatively, the patient may receive J1814 in an infusion clinic or hospital outpatient setting when transitioning to or evaluating lyumjev therapy. The clinical workflow includes verification of diagnosis and prior insulin regimen, assessment of blood glucose records or continuous glucose monitor data, education on dosing and injection technique, prescription and dispensing of lyumjev measured in 5-unit increments, documentation of dose administered or provided, and coordination with pharmacy for coverage and supplies. For patients receiving an in-clinic supervised administration (for example during a monitored titration or inpatient/off-label use), nursing documents the units given, lot number, and any immediate adverse reactions. Billing uses J1814 reported per 5 units of lyumjev when applicable to payor policy and the site of service (clinic, outpatient hospital, infusion center, or inpatient billing where permitted).
Coding Specifications
| Modifier | Description | When to Use |
|---|